Skip to main content

DISEÑO DE ESTRATEGIAS PARA CONTROLAR LA PROLIFERACION, DIFERENCIACION Y MADURACION DE CARDIOMIOCITOS HUMANO

SAF2015-69706-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2015
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Dirección General de Investigación Científica y Técnica
Beneficiary centre FUNDACIO PRIVADA CENTRE DE MEDICINA REGENERATIVA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Patient-specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson's disease

  • di Domenico, Angelique
  • Carola, Giulia
  • Calatayud, Carles
  • Pons Espinal, Meritxell, 1986-
  • Muñoz, Juan Pablo
  • Richaud Patin, Yvonne
  • Fernández Carasa, Irene
  • Gut, Marta
  • Faella, Armida
  • Parameswaran, Janani, 1990-
  • Soriano i Fradera, Jordi
  • Ferrer, Isidre
  • Tolosa, Eduard
  • Zorzano, Antonio
  • Cuervo, Ana Maria
  • Raya Chamorro, Ángel
  • Consiglio, Antonella
Parkinson's disease (PD) is associated with the degeneration of ventral midbrain dopaminergic neurons (vmDAns) and the accumulation of toxic α-synuclein. A non-cell-autonomous contribution, in particular of astrocytes, during PD pathogenesis has been suggested by observational studies, but remains to be experimentally tested. Here, we generated induced pluripotent stem cell-derived astrocytes and neurons from familial mutant LRRK2 G2019S PD patients and healthy individuals. Upon co-culture on top of PD astrocytes, control vmDAns displayed morphological signs of neurodegeneration and abnormal, astrocyte-derived α-synuclein accumulation. Conversely, control astrocytes partially prevented the appearance of disease-related phenotypes in PD vmDAns. We additionally identified dysfunctional chaperone-mediated autophagy (CMA), impaired macroautophagy, and progressive α-synuclein accumulation in PD astrocytes. Finally, chemical enhancement of CMA protected PD astrocytes and vmDAns via the clearance of α-synuclein accumulation. Our findings unveil a crucial non-cell-autonomous contribution of astrocytes during PD pathogenesis, and open the path to exploring novel therapeutic strategies aimed at blocking the pathogenic cross talk between neurons and glial cells., We are thankful to Mark Cookson for the LRRK2 G2019S plasmid (Addgene Plasmid No. 29401). We are grateful to the Advanced Fluorescence Microscopy Unit of the Institute of Biomedicine of the University of Barcelona (especially to Elena Rebollo Arredondo). Research from the authors' laboratories is supported by the European Research Council (ERC) (2012-StG-311736-PD-HUMMODEL), the Spanish Ministry of Economy and Competitiveness (MINECO) (FIS2016-78507-C2-2-P, SAF2015-69706-R, and BFU2016-80870-P), Instituto de Salud Carlos III (ISCIII/FEDER) (Red de Terapia Celular [TerCel] RD16/0011/0024), AGAUR (2014-SGR-878 and 2017-SGR-899), and CERCA Program/Generalitat de Catalunya. A.D. is supported by the PD-HUMMODEL ERC-Ideas PhD fellowship. C.C. and G.C. are partially supported by predoctoral fellowships from the Spanish Ministry of Education (MEC) (FPU12/03332) and MINECO (BES-2014-069603), respectively.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

GATA2 promotes hematopoietic development and represses cardiac differentiation of human mesoderm

  • Castaño, Julio
  • Aranda Aragón, Sergio
  • Blanco, Enrique
  • Mereu, Elisabetta
  • Heyn, Holger
  • Di Croce, Luciano
  • Giorgetti, Alessandra
In vertebrates, GATA2 is a master regulator of hematopoiesis and is expressed throughout embryo development and in adult life. Although the essential role of GATA2 in mouse hematopoiesis is well established, its involvement during early human hematopoietic development is not clear. By combining time-controlled overexpression of GATA2 with genetic knockout experiments, we found that GATA2, at the mesoderm specification stage, promotes the generation of hemogenic endothelial progenitors and their further differentiation to hematopoietic progenitor cells, and negatively regulates cardiac differentiation. Surprisingly, genome-wide transcriptional and chromatin immunoprecipitation analysis showed that GATA2 bound to regulatory regions, and repressed the expression of cardiac development-related genes. Moreover, genes important for hematopoietic differentiation were upregulated by GATA2 in a mostly indirect manner. Collectively, our data reveal a hitherto unrecognized role of GATA2 as a repressor of cardiac fates, and highlight the importance of coordinating the specification and repression of alternative cell fates., The authors thank Dr Catherine Porcher (University of Oxford) for the SCL antibody, Olalla Iglesias, Anna Duarri, and Yvonne Richaud for help with cell differentiation, and core of CMRB for technical assistance. A.G. is supported by Ramón y Cajal Program (RyC-2013-13221) and MINECO (SAF2016-80205-R). C.B. is supported by the FIS/ISCIII (PI14/01191), Spanish Cancer Association (CI15152720BUEN). J.L.M. is supported by ISCIII (CA18/00045) and by the European Social Fund (ESF). M.R. is supported by MINECO (SAF2015-73226-JIN). P.M. is funded by the PERIS Program of the Generalitat de Catalunya and by the Obra Social la Caixa-Fundacion Josep Carreras. H.H. is supported by Miguel Servet (CP14/00229). CNAG-CRG Core funding is from the ISCIII, and the Generalitat de Catalunya. Gottgens laboratory is supported by The Wellcome Trust, MRC, CRUK, NIH-NIDDK, and core support grants by The Wellcome Trust to the Wellcome and MRC Cambridge Stem Cell Institute. Additional funding came from Generalitat de Catalunya (2014-SGR-1460 and PERIS SLT002/16/00234); MINECO (SAF2015-69706-R); ISCIII/FEDER (RD16/0011/0024); ACCIÓ/FEDER (AdvanceCat); Fundació la Marató de TV3 (201534-30); and CERCA Program/Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CRISPR/Cas9-mediated generation of a tyrosine hydroxylase reporter iPSC line for live imaging and isolation of dopaminergic neurons

  • Calatayud, Carles
  • Carola, Giulia
  • Fernández-Carasa, Irene
  • Valtorta, Marco
  • Jiménez-Delgado, Senda
  • Díaz, Mònica
  • Soriano-Fradera, Jordi
  • Cappelletti, Graziella
  • García-Sancho, Javier
  • Raya, Ángel
  • Consiglio, Antonella
Patient-specific induced pluripotent stem cells (iPSCs) are a powerful tool to investigate the molecular mechanisms underlying Parkinson’s disease (PD), and might provide novel platforms for systematic drug screening. Several strategies have been developed to generate iPSC-derived tyrosine hydroxylase (TH)-positive dopaminergic neurons (DAn), the clinically relevant cell type in PD; however, they often result in mixed neuronal cultures containing only a small proportion of TH-positive DAn. To overcome this limitation, we used CRISPR/Cas9-based editing to generate a human iPSC line expressing a fluorescent protein (mOrange) knocked-in at the last exon of the TH locus. After differentiation of the TH-mOrange reporter iPSC line, we confirmed that mOrange expression faithfully mimicked endogenous TH expression in iPSC-derived DAn. We also employed calcium imaging techniques to determine the intrinsic functional differences between dopaminergic and non-dopaminergic ventral midbrain neurons. Crucially, the brightness of mOrange allowed direct visualization of TH-expressing cells in heterogeneous cultures, and enabled us to isolate live mOrange-positive cells through fluorescence-activated cell sorting, for further differentiation. This technique, coupled to refined imaging and data processing tools, could advance the investigation of PD pathogenesis and might offer a platform to test potential new therapeutics for PD and other neurodegenerative diseases., Research from the authors’ laboratories is supported by the European Research Council-ERC (2012-StG-311736-PD-HUMMODEL), the European Union’s Horizon 2020 Program (MESOBRAIN project; grant agreement No 713140), the Spanish Ministry of Economy and Competitiveness-MINECO (SAF2015-69706-R; BFU2017-83066-P; and BFU2016-80870-P), Instituto de Salud Carlos III-ISCIII/FEDER (Red de Terapia Celular - TerCel RD16/0011/0003 and RD16/0011/0024; PIE12/00061), AGAUR (2017-SGR-899 and 2017-SGR-1061), and CERCA Program/Generalitat de Catalunya. C.C. is supported by the PD-HUMMODEL European Research Council (ERC)- Ideas PhD fellowship. G.C. is partially supported by pre-doctoral fellowship from Spanish Economy and Competitiveness-MINECO (BES-2014-069603)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

GATA2 promotes hematopoietic development and represses cardiac differentiation of human mesoderm

  • Castaño, Julio
  • Aranda Aragón, Sergio
  • Blanco, Enrique
  • Mereu, Elisabetta
  • Heyn, Holger
  • Di Croce, Luciano
  • Giorgetti, Alessandra
In vertebrates, GATA2 is a master regulator of hematopoiesis and is expressed throughout embryo development and in adult life. Although the essential role of GATA2 in mouse hematopoiesis is well established, its involvement during early human hematopoietic development is not clear. By combining time-controlled overexpression of GATA2 with genetic knockout experiments, we found that GATA2, at the mesoderm specification stage, promotes the generation of hemogenic endothelial progenitors and their further differentiation to hematopoietic progenitor cells, and negatively regulates cardiac differentiation. Surprisingly, genome-wide transcriptional and chromatin immunoprecipitation analysis showed that GATA2 bound to regulatory regions, and repressed the expression of cardiac development-related genes. Moreover, genes important for hematopoietic differentiation were upregulated by GATA2 in a mostly indirect manner. Collectively, our data reveal a hitherto unrecognized role of GATA2 as a repressor of cardiac fates, and highlight the importance of coordinating the specification and repression of alternative cell fates., The authors thank Dr Catherine Porcher (University of Oxford) for the SCL antibody, Olalla Iglesias, Anna Duarri, and Yvonne Richaud for help with cell differentiation, and core of CMRB for technical assistance. A.G. is supported by Ramón y Cajal Program (RyC-2013-13221) and MINECO (SAF2016-80205-R). C.B. is supported by the FIS/ISCIII (PI14/01191), Spanish Cancer Association (CI15152720BUEN). J.L.M. is supported by ISCIII (CA18/00045) and by the European Social Fund (ESF). M.R. is supported by MINECO (SAF2015-73226-JIN). P.M. is funded by the PERIS Program of the Generalitat de Catalunya and by the Obra Social la Caixa-Fundacion Josep Carreras. H.H. is supported by Miguel Servet (CP14/00229). CNAG-CRG Core funding is from the ISCIII, and the Generalitat de Catalunya. Gottgens laboratory is supported by The Wellcome Trust, MRC, CRUK, NIH-NIDDK, and core support grants by The Wellcome Trust to the Wellcome and MRC Cambridge Stem Cell Institute. Additional funding came from Generalitat de Catalunya (2014-SGR-1460 and PERIS SLT002/16/00234); MINECO (SAF2015-69706-R); ISCIII/FEDER (RD16/0011/0024); ACCIÓ/FEDER (AdvanceCat); Fundació la Marató de TV3 (201534-30); and CERCA Program/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Patient-specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson's disease

  • di Domenico, Angelique
  • Carola, Giulia
  • Calatayud, Carles
  • Pons Espinal, Meritxell, 1986-
  • Muñoz, Juan Pablo
  • Richaud Patin, Yvonne
  • Fernández Carasa, Irene
  • Gut, Marta
  • Faella, Armida
  • Parameswaran, Janani, 1990-
  • Soriano i Fradera, Jordi
  • Ferrer, Isidre
  • Tolosa, Eduard
  • Zorzano, Antonio
  • Cuervo, Ana Maria
  • Raya Chamorro, Ángel
  • Consiglio, Antonella
Parkinson's disease (PD) is associated with the degeneration of ventral midbrain dopaminergic neurons (vmDAns) and the accumulation of toxic α-synuclein. A non-cell-autonomous contribution, in particular of astrocytes, during PD pathogenesis has been suggested by observational studies, but remains to be experimentally tested. Here, we generated induced pluripotent stem cell-derived astrocytes and neurons from familial mutant LRRK2 G2019S PD patients and healthy individuals. Upon co-culture on top of PD astrocytes, control vmDAns displayed morphological signs of neurodegeneration and abnormal, astrocyte-derived α-synuclein accumulation. Conversely, control astrocytes partially prevented the appearance of disease-related phenotypes in PD vmDAns. We additionally identified dysfunctional chaperone-mediated autophagy (CMA), impaired macroautophagy, and progressive α-synuclein accumulation in PD astrocytes. Finally, chemical enhancement of CMA protected PD astrocytes and vmDAns via the clearance of α-synuclein accumulation. Our findings unveil a crucial non-cell-autonomous contribution of astrocytes during PD pathogenesis, and open the path to exploring novel therapeutic strategies aimed at blocking the pathogenic cross talk between neurons and glial cells., We are thankful to Mark Cookson for the LRRK2 G2019S plasmid (Addgene Plasmid No. 29401). We are grateful to the Advanced Fluorescence Microscopy Unit of the Institute of Biomedicine of the University of Barcelona (especially to Elena Rebollo Arredondo). Research from the authors' laboratories is supported by the European Research Council (ERC) (2012-StG-311736-PD-HUMMODEL), the Spanish Ministry of Economy and Competitiveness (MINECO) (FIS2016-78507-C2-2-P, SAF2015-69706-R, and BFU2016-80870-P), Instituto de Salud Carlos III (ISCIII/FEDER) (Red de Terapia Celular [TerCel] RD16/0011/0024), AGAUR (2014-SGR-878 and 2017-SGR-899), and CERCA Program/Generalitat de Catalunya. A.D. is supported by the PD-HUMMODEL ERC-Ideas PhD fellowship. C.C. and G.C. are partially supported by predoctoral fellowships from the Spanish Ministry of Education (MEC) (FPU12/03332) and MINECO (BES-2014-069603), respectively.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The small GTPase RAC1/CED-10 is essential in maintaining dopaminergic neuron function and survival against α-synuclein-induced toxicity

  • Kim, Hanna
  • Calatayud, Carles|||0000-0003-0032-4198
  • Guha, Sanjib
  • Fernandez Carasa, Irene|||0000-0002-8195-3510
  • Berkowitz, Laura
  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Ezquerra, Mario|||0000-0003-3246-6641
  • Fernández-Santiago, Rubén|||0000-0002-4582-0702
  • Kapahi, Pankaj
  • Raya, Ángel|||0000-0003-2189-9775
  • Miranda Vizuete, Antonio
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Caldwell, Kim A.
  • Caldwell, Guy A.
  • Consiglio, Antonella
  • Dalfo, Esther|||0000-0003-4677-8515
Parkinson's disease is associated with intracellular α-synuclein accumulation and ventral midbrain dopaminergic neuronal death in the Substantia Nigra of brain patients. The Rho GTPase pathway, mainly linking surface receptors to the organization of the actin and microtubule cytoskeletons, has been suggested to participate to Parkinson's disease pathogenesis. Nevertheless, its exact contribution remains obscure. To unveil the participation of the Rho GTPase family to the molecular pathogenesis of Parkinson's disease, we first used C elegans to demonstrate the role of the small GTPase RAC1 (ced-10 in the worm) in maintaining dopaminergic function and survival in the presence of alpha-synuclein. In addition, ced-10 mutant worms determined an increase of alpha-synuclein inclusions in comparison to control worms as well as an increase in autophagic vesicles. We then used a human neuroblastoma cells (M17) stably over-expressing alpha-synuclein and found that RAC1 function decreased the amount of amyloidogenic alpha-synuclein. Further, by using dopaminergic neurons derived from patients of familial LRRK2-Parkinson's disease we report that human RAC1 activity is essential in the regulation of dopaminergic cell death, alpha-synuclein.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

GATA2 Promotes Hematopoietic Development and Represses Cardiac Differentiation of Human Mesoderm

  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Aranda, Sergi|||0000-0003-3853-430X
  • Bueno, Clara|||0000-0003-1442-6216
  • Calero-Nieto, Fernando|||0000-0003-3358-8253
  • Mejia-Ramirez, Eva|||0000-0003-1251-5223
  • Mosquera, José Luis|||0000-0002-7852-4993
  • Blanco, Enrique|||0000-0001-6261-7370
  • Wang, Xiaonan|||0000-0003-3759-778X
  • Prieto, Cristina|||0000-0002-0812-8100
  • Zabaleta, Lorea
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Rovira, Meritxell|||0000-0002-0538-4846
  • Jiménez-Delgado, Senda
  • Matson, Daniel Rusch|||0000-0003-1430-3128
  • Heyn, Holger|||0000-0002-3276-1889
  • Bresnick, Emery H.
  • Göttgens, Berthold|||0000-0001-6302-5705
  • Di Croce, Luciano|||0000-0003-3488-6228
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Raya, Ángel|||0000-0003-2189-9775
  • Giorgetti, Alessandra|||0000-0001-5803-3567
In vertebrates, GATA2 is a master regulator of hematopoiesis and is expressed throughout embryo development and in adult life. Although the essential role of GATA2 in mouse hematopoiesis is well established, its involvement during early human hematopoietic development is not clear. By combining time-controlled overexpression of GATA2 with genetic knockout experiments, we found that GATA2, at the mesoderm specification stage, promotes the generation of hemogenic endothelial progenitors and their further differentiation to hematopoietic progenitor cells, and negatively regulates cardiac differentiation. Surprisingly, genome-wide transcriptional and chromatin immunoprecipitation analysis showed that GATA2 bound to regulatory regions, and repressed the expression of cardiac development-related genes. Moreover, genes important for hematopoietic differentiation were upregulated by GATA2 in a mostly indirect manner. Collectively, our data reveal a hitherto unrecognized role of GATA2 as a repressor of cardiac fates, and highlight the importance of coordinating the specification and repression of alternative cell fates.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Generation of integration-free induced pluripotent stem cell lines derived from two patients with X-linked Alport syndrome (XLAS)

  • Kuebler, Bernd|||0000-0002-4472-871X
  • Aran, Begoña|||0000-0002-5011-7755
  • Miquel-Serra, Laia|||0000-0001-8382-3341
  • Muñoz, Yolanda
  • Ars, Elisabet|||0000-0002-4118-4358
  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Furlano, Monica|||0000-0003-1025-3901
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Martí, Mercè|||0000-0002-1846-0043
  • Veiga, Anna|||0000-0002-0943-9904
  • Raya, Ángel|||0000-0003-2189-9775
Skin biopsies were obtained from two male patients with X-linked Alport syndrome (XLAS) with hemizygous COL4A5 mutations in exon 41 or exon 46. Dermal fibroblasts were extracted and reprogrammed by nucleofection with episomal plasmids carrying OCT3/4, SOX2, KLF4 LIN28, L-MYC and p53 shRNA. The generated induced Pluripotent Stem Cell (iPSC) lines AS-FiPS2-Ep6F-28 and AS-FiPS3-Ep6F-9 were free of genomically integrated reprogramming genes, had the specific mutations, a stable karyotype, expressed pluripotency markers and generated embryoid bodies which were differentiated towards the three germ layers in vitro. These iPSC lines offer a useful resource to study Alport syndrome pathomechanisms and drug testing.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Integration-free induced pluripotent stem cells derived from a patient with autosomal recessive Alport syndrome (ARAS)

  • Kuebler, Bernd|||0000-0002-4472-871X
  • Aran, Begoña|||0000-0002-5011-7755
  • Miquel-Serra, Laia|||0000-0001-8382-3341
  • Muñoz, Yolanda
  • Ars, Elisabet|||0000-0002-4118-4358
  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Furlano, Monica|||0000-0003-1025-3901
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Martí, Mercè|||0000-0002-1846-0043
  • Veiga, Anna|||0000-0002-0943-9904
  • Raya, Ángel|||0000-0003-2189-9775
A skin biopsy was obtained from a 25-year-old female patient with autosomal recessive Alport syndrome (ARAS) with the homozygous COL4A3 mutation c.345delG, p.(P166Lfs*37). Dermal fibroblasts were derived and reprogrammed by nucleofection with episomal plasmids carrying OCT3/4, SOX2, KLF4 LIN28, L-MYC and p53shRNA. The generated induced Pluripotent Stem Cell (iPSC) clone AS FiPS1 Ep6F-2 was free of genomically integrated reprogramming genes, had the specific homozygous mutation, a stable karyotype, expressed pluripotency markers and generated embryoid bodies which were differentiated towards the three germ layers in vitro. This iPSC line offers a useful resource to study Alport syndrome pathomechanisms and drug testing.